Job Title: Associate Director, Health Economics
Location: Zug Switzerland or London UK (Remote/Hybrid)
Industry: Biotech | Rare Disease
Company Overview
Our client is an innovative biotech company focused on rare diseases (oncology), dedicated to transforming patient lives through ground-breaking therapies. With a strong pipeline of advanced treatments, the company is committed to delivering high-value healthcare solutions that address significant unmet medical needs.
To support its growing portfolio, the company is seeking an Associate Director, Health Economics to develop and execute health economic strategies that drive pricing, market access, and reimbursement decisions across Europe. The role will play a critical part in ensuring that therapies reach patients by demonstrating their clinical and economic value to payers, policymakers, and healthcare providers.
Role Overview
The Associate Director, Health Economics will be responsible for leading health economic modeling, generating evidence to support HTA submissions, and shaping value demonstration strategies for rare disease therapies. This is a strategic role requiring expertise in health economics, cost-effectiveness analysis, and payer engagement in European markets. The successful candidate will work closely with cross-functional teams, including Market Access, Medical Affairs, and Regulatory Affairs, to support global and local reimbursement strategies.
Key Responsibilities
* Develop and execute health economic strategies to support pricing, reimbursement, and market access for rare disease therapies.
* Lead the design and development of cost-effectiveness, budget impact, and burden of illness models to support value propositions.
* Collaborate with cross-functional teams to generate real-world evidence (RWE) and health economic data to support product value and differentiation.
* Support and develop HTA and payer submissions across key European markets.
* Conduct literature reviews, systematic reviews, and meta-analyses to strengthen evidence generation and economic models.
* Provide strategic input on clinical trial design to ensure the generation of relevant health economic endpoints.
* Engage with key external stakeholders, including payers, HTA bodies, policymakers, and patient advocacy groups, to shape market access strategy.
* Partner with local affiliates to tailor global health economic models and dossiers for country-specific requirements.
* Stay ahead of emerging trends in health economics, reimbursement policies, and value-based pricing models in rare disease markets.
Key Requirements
* Advanced degree in Health Economics, Pharmacoeconomics, Public Health, Epidemiology, or a related field.
* Proven experience in health economics within the pharmaceutical or biotech industry, with a strong focus on rare diseases or specialty medicines.
* Expertise in health economic modeling, cost-effectiveness analysis, and budget impact assessments.
* In-depth understanding of European HTA requirements, reimbursement processes, and payer engagement.
* Experience working on HTA submissions in major European markets (e.g., NICE, G-BA, HAS, AIFA, TLV).
* Strong analytical skills and the ability to interpret complex data to support pricing and market access strategies.
* Ability to communicate complex health economic concepts to both technical and non-technical stakeholders.
* Experience in real-world evidence generation and patient-reported outcomes is an advantage.
* Highly motivated, with the ability to work independently and in a cross-functional, international team.
Opportunity
This role provides a unique opportunity to shape health economic strategy in the rare disease space, working with an innovative biotech company at the forefront of life-changing therapies. The successful candidate will play a key role in ensuring that novel treatments gain optimal market access and reimbursement across Europe. Competitive compensation and flexible working arrangements are offered.
To discuss this opportunity further, please apply or contact us for a confidential conversation.